Advertisement

Acta Parasitologica

, Volume 64, Issue 3, pp 645–651 | Cite as

A Laboratory Strain of Leishmania major: Protective Effects on Experimental Leishmaniasis

  • Mehdi Namavari
  • Fatemeh NamaziEmail author
  • Reza Asadi-Manesh
  • Mohammad H. Hosseini
  • Saeed Nazifi
  • Mohammad Asadpour
Original Paper
  • 22 Downloads

Abstract

Purpose

Leishmaniasis, as one of the most important vector-borne and zoonotic diseases, can be seen in different forms and is more prevalent in developing countries worldwide. Due to the absence of effective strategies in its prevention, treatment, and control, investigation of effective control strategies against the disease is necessary. In this research, we evaluated the immunogenicity of a cold-adapted laboratory strain of Leishmania major (LMC) in the mouse model.

Methods

Twenty BALB/c mice were divided into two groups. LMC group received 4 × 106 of LMC strain in 0.5 ml DMEM, and VLM group, as the control group, received 0.5 ml Dulbecco’s modified Eagle’s medium. Both groups were challenged with virulent L. major 3 weeks after inoculation.

Results

The data obtained from the analysis of immune responses and histopathological changes interestingly revealed protection against L. major in immunized mice. Compared with the VLM group, the mice immunized with LMC strain of L. major in the LMC group showed a significant increase in IFN-γ and IgG2a levels (P < 0.05) which are important indexes for Th1-related immune responses. Additionally, significant differences in concentration of IgG1 and IgG total before and after the challenge was observed in LMC group (P < 0.05). Furthermore, the immunized mice showed a significant reduction in mean sizes of skin lesion and liver damage compared to the VLM group.

Conclusion

Based on the present findings on immunogenicity of LMC strain, it seems this strain is able to induce both humoral and cellular immunity and a significant protection against L. major in the mouse model.

Keywords

Leishmania major Cold-adapted laboratory strain Immunogenicity Histopathology BALB/c mice 

Notes

Acknowledgements

This work was supported by the Research Council of Shiraz University and School of Veterinary Medicine, Shiraz University (94GCU5M83832) and the Razi Vaccine and Serum Research Institute, Shiraz Branch, Agricultural Research, Education and Extension Organization (AREEO).

Compliance with Ethical Standards

Conflict of Interest

The authors have no competing interests.

References

  1. 1.
    Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7:e35671CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Asadi-Manesh R (2016) Histopathological and immunogenic study of Leishmania major LMC strain in inbred Balb/c mice. DVM Thesis. Shiraz University, IranGoogle Scholar
  3. 3.
    Badiee A, Jaafari MR, Khamesipour A (2007) Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp Parasitol 115:27–134CrossRefGoogle Scholar
  4. 4.
    Baptista-Fernandes T, Marques C, Rodrigues OR, Santos-Gomes GM (2007) Intra-specific variability of virulence in Leishmania infantum zymodeme MON-1 strains. Comp Immunol Microbiol Infect Dis 30:41–53CrossRefGoogle Scholar
  5. 5.
    Boom WH, Liebster L, Abbas A, Titus R (1990) Patterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolution. Infect Immun 58:3863–3870PubMedPubMedCentralGoogle Scholar
  6. 6.
    Campos-Neto A, Webb J, Greeson K, Coler R, Skeiky Y, Reed S (2002) Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun 70:2828–2836CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21:244–249CrossRefGoogle Scholar
  8. 8.
    Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG (1993) Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette–Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA 90:11473–11477CrossRefGoogle Scholar
  9. 9.
    Cox FE (1996) The Wellcome Trust illustrated history of tropical diseases. Wellcome Trust, LondonGoogle Scholar
  10. 10.
    Croft SL, Coombs GH (2003) Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19:502–508CrossRefGoogle Scholar
  11. 11.
    Dey R, Dagur PK, Selvapandiyan A, McCoy JP, Salotra P, Duncan R, Nakhasi HL (2013) Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol 190:2138–2149CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dunning N (2009) Leishmania vaccines: from leishmanization to the era of DNA technology. Biosci Horizons 2:73–82CrossRefGoogle Scholar
  13. 13.
    Fiuza JA, Gannavaram S, da Costa Santiago H, Selvapandiyan A, Souza DM, Passos LS et al (2015) Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum. Vaccine 33:280–288CrossRefGoogle Scholar
  14. 14.
    Gibson-Corley KN, Olivier AK, Meyerholz DK (2013) Principles for valid histopathologic scoring in research. Vet Pathol 50(6):1007–1015CrossRefGoogle Scholar
  15. 15.
    Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME (2016) Status of vaccine research and development of vaccines for leishmaniasis. Vaccine 34:2992–2995CrossRefGoogle Scholar
  16. 16.
    Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14:229–243CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hashemi-Fesharaki R, Ale-Agha S, Habibi G, Manhouri H, Esmail-Nia K, Mohammadi A (1998) Production of inactivated wet rural Leishmania major. Iran J Med Sci 23:74–80Google Scholar
  18. 18.
    Jaafari MR, Ghafarian A, Farrokh-Gisour A, Samiei A, Kheiri MT, Mahboudi F et al (2006) Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24:5708–5717CrossRefGoogle Scholar
  19. 19.
    Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B et al (2000) Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356:1565–1569CrossRefGoogle Scholar
  20. 20.
    Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S et al (2005) Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23:3642–3648CrossRefGoogle Scholar
  21. 21.
    Lage DP, Martins VT, Duarte MC, Costa LE, Garde E, Dimer LM et al (2016) A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis. Parasitol Res 115:1649–1658CrossRefGoogle Scholar
  22. 22.
    Liu D, Kebaier C, Pakpour N, Capul AA, Beverley SM, Scott P et al (2009) Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions. Infect Immun 77:3272–3283CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedPubMedCentralGoogle Scholar
  24. 24.
    Mayrik W, Botelho ACdC, Magalhães PA, Batista SM, Lima AdO, Genaro O et al (2006) Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop 39:14–21CrossRefGoogle Scholar
  25. 25.
    McMahon-Pratt D, Rodriguez D, Rodriguez J, Zhang Y, Manson K, Bergman C et al (1993) Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 61:3351–3359PubMedPubMedCentralGoogle Scholar
  26. 26.
    Modabber F (1989) Experiences with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology 98:S49–S60CrossRefGoogle Scholar
  27. 27.
    Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL et al (1999) A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17:466–472CrossRefGoogle Scholar
  28. 28.
    Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M (1982) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull de la Société de Pathologie Exotique 76:377–383Google Scholar
  29. 29.
    Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K et al (2008) First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26:6759–6767CrossRefGoogle Scholar
  30. 30.
    Okwor I, Uzonna J (2009) Vaccines and vaccination strategies against human cutaneous leishmaniasis. Human Vaccine 5:291–301CrossRefGoogle Scholar
  31. 31.
    Ramírez L, Santos DM, Souza AP, Coelho EA, Barral A, Alonso C et al (2013) Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis. Vaccine 31:1312–1319CrossRefGoogle Scholar
  32. 32.
    Rivier D, Shah R, Bovay P, Mauel J (1993) Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol 15:75–84CrossRefGoogle Scholar
  33. 33.
    Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2:845–858CrossRefGoogle Scholar
  34. 34.
    Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM (1990) Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med 171:115–127CrossRefGoogle Scholar
  35. 35.
    Scott P, Pearce E, Natovitz P, Sher A (1987) Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 139:221–227PubMedGoogle Scholar
  36. 36.
    Selvapandiyan A, Dey R, Gannavaram S, Solanki S, Salotra P, Nakhasi HL (2014) Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis. Vaccine 32:3895–3901CrossRefGoogle Scholar
  37. 37.
    Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL (2009) Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol 183:1813–1820CrossRefGoogle Scholar
  38. 38.
    Silvestre R, Cordeiro-da-Silva A, Ouaissi A (2008) Live attenuated Leishmania vaccines: a potential strategic alternative. Arch Immunol Ther Exp 56:123CrossRefGoogle Scholar
  39. 39.
    Srivastava S, Shankar P, Mishra J, Singh S (2016) Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasites Vectors 9:277CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Tewary P, Sukumaran B, Saxena S, Madhubala R (2004) Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 22:3053–3060CrossRefGoogle Scholar
  41. 41.
    Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AS et al (2004) Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun 72:5654–5661CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Uzonna JE, Joyce KL, Scott P (2004) Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon γ-producing CD8 + T cells. J Exp Med 199:1559–1566CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N et al (2014) Enhanced protective efficacy of nonpathogenic recombinant Leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. PLoS Negl Trop Dis 8:e2751CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Zandieh M, Kashi T, Taheri T, Zahedifard F, Taslimi Y, Doustdary M et al (2015) Assessment of protection induced by DNA and live vaccine encoding Leishmania MHC class I restricted epitopes against L. major challenge in Balb/c mice model. J Microb Biochem Technol 7(6):427–438CrossRefGoogle Scholar

Copyright information

© Witold Stefański Institute of Parasitology, Polish Academy of Sciences 2019

Authors and Affiliations

  • Mehdi Namavari
    • 1
  • Fatemeh Namazi
    • 2
    Email author
  • Reza Asadi-Manesh
    • 3
  • Mohammad H. Hosseini
    • 1
  • Saeed Nazifi
    • 4
  • Mohammad Asadpour
    • 2
  1. 1.Razi Vaccine and Serum Research Institute, Shiraz BranchAgricultural Research, Education and Extension Organization (AREEO)ShirazIran
  2. 2.Department of Pathobiology, School of Veterinary MedicineShiraz UniversityShirazIran
  3. 3.School of Veterinary MedicineShiraz UniversityShirazIran
  4. 4.Department of Clinical Sciences, School of Veterinary MedicineShiraz UniversityShirazIran

Personalised recommendations